98 related articles for article (PubMed ID: 22716238)
1. Changes in circulating biomarkers during a single hemodialysis session.
Yamamoto T; Nascimento MM; Hayashi SY; Qureshi AR; Waniewski J; Brodin LÅ; Anderstam B; Lind B; Riella MC; Seeberger A; Lindholm B
Hemodial Int; 2013 Jan; 17(1):59-66. PubMed ID: 22716238
[TBL] [Abstract][Full Text] [Related]
2. Potential Correlation Between Circulating Fetuin-A and Pentraxin-3 With Biochemical Parameters of Calcification in Hemodialysis Patients.
Hashemi J; Joshaghani HR; Akaberi A; Hesari Z; Ghanbari R; Mohammadzadeh M; Golshan AR
Arch Iran Med; 2017 Dec; 20(12):752-755. PubMed ID: 29664315
[TBL] [Abstract][Full Text] [Related]
3. Plasma pentraxin-3 as a marker of bioincompatibility in hemodialysis patients.
Oldani S; Finazzi S; Bottazzi B; Garlanda C; Baldassarre E; Valaperta S; Cuccovillo I; Albini M; Child M; Montanelli A; Graziani G; Badalamenti S
J Nephrol; 2012; 25(1):120-6. PubMed ID: 21725917
[TBL] [Abstract][Full Text] [Related]
4. Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients.
Xu Y; Ding X; Zou J; Liu Z; Jiang S; Xu S; Shen B; Chen Y; Shan Y; Cao X
Ren Fail; 2011; 33(10):998-1004. PubMed ID: 22013933
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines.
Malaponte G; Libra M; Bevelacqua Y; Merito P; Fatuzzo P; Rapisarda F; Cristina M; Naselli G; Stivala F; Mazzarino MC; Castellino P
Int J Mol Med; 2007 Oct; 20(4):471-81. PubMed ID: 17786277
[TBL] [Abstract][Full Text] [Related]
6. Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation.
Sjöberg B; Qureshi AR; Anderstam B; Alvestrand A; Bárány P
Blood Purif; 2012; 34(3-4):290-7. PubMed ID: 23235124
[TBL] [Abstract][Full Text] [Related]
7. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease.
Boehme M; Kaehne F; Kuehne A; Bernhardt W; Schröder M; Pommer W; Fischer C; Becker H; Müller C; Schindler R
Nephrol Dial Transplant; 2007 Aug; 22(8):2224-9. PubMed ID: 17496115
[TBL] [Abstract][Full Text] [Related]
8. Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study.
Szklarek-Kubicka M; Fijałkowska-Morawska J; Zaremba-Drobnik D; Uciński A; Czekalski S; Nowicki M
J Ren Nutr; 2009 Nov; 19(6):487-93. PubMed ID: 19616450
[TBL] [Abstract][Full Text] [Related]
9. Relationships between plasma pentraxin 3 levels and inflammation markers patients with tunneled permanent catheter in hemodialysis.
Yigit IP; Dogukan A; Taskapan H; Comert M; Ilhan N; Ulu R; Aygen B
J Vasc Access; 2015; 16(5):377-81. PubMed ID: 26070095
[TBL] [Abstract][Full Text] [Related]
10. Serum Fetuin-A and Pentraxin3 in hemodialysis and renal transplant patients.
Argani H; Ghorbanihaghjo A; Panahi G; Rashtchizadeh N; Safa J; Meimand SM
Clin Biochem; 2012 Jul; 45(10-11):775-9. PubMed ID: 22546644
[TBL] [Abstract][Full Text] [Related]
11. Hemodialysis induces p66(shc) gene expression in nondiabetic humans: correlations with oxidative stress and systemic inflammation.
Zanetti M; Barazzoni R; Gortan Cappellari G; Burekovic I; Bosutti A; Stocca A; Bianco F; Ianche M; Panzetta G; Guarnieri G
J Ren Nutr; 2011 Sep; 21(5):401-9. PubMed ID: 21439852
[TBL] [Abstract][Full Text] [Related]
12. Ceruloplasmin and acute phase protein levels are associated with cardiovascular disease in chronic dialysis patients.
Panichi V; Taccola D; Rizza GM; Consani C; Migliori M; Filippi C; Paoletti S; Sidoti A; Borracelli D; Panicucci E; Giovannini L
J Nephrol; 2004; 17(5):715-20. PubMed ID: 15593040
[TBL] [Abstract][Full Text] [Related]
13. Pentraxin 3 and C-reactive protein as inflammatory markers after a kidney transplant.
Gursu M; Celik K; Ozturk S; Turkmen A; Gorcin S; Kocak B; Sari S; Koldas M; Feyizoglu H; Kazancioglu R
Exp Clin Transplant; 2014 Aug; 12(4):295-9. PubMed ID: 24568622
[TBL] [Abstract][Full Text] [Related]
14. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients.
Bevelacqua V; Libra M; Mazzarino MC; Gangemi P; Nicotra G; Curatolo S; Massimino D; Plumari A; Merito P; Valente G; Stivala F; La Greca S; Malaponte G
Int J Mol Med; 2006 Sep; 18(3):415-23. PubMed ID: 16865225
[TBL] [Abstract][Full Text] [Related]
15. Effect of a single hemodialysis session on inflammatory markers.
Bitla AR; Reddy PE; Manohar SM; Vishnubhotla SV; Pemmaraju Venkata Lakshmi Narasimha SR
Hemodial Int; 2010 Oct; 14(4):411-7. PubMed ID: 20955274
[TBL] [Abstract][Full Text] [Related]
16. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality.
Suliman ME; Qureshi AR; Carrero JJ; Bárány P; Yilmaz MI; Snaedal-Jonsdottir S; Alvestrand A; Heimbürger O; Lindholm B; Stenvinkel P
QJM; 2008 May; 101(5):397-405. PubMed ID: 18292098
[TBL] [Abstract][Full Text] [Related]
17. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
18. Changes in the inflammatory and oxidative stress markers during a single hemodialysis session in patients with chronic kidney disease.
Sangeetha Lakshmi B; Harini Devi N; Suchitra MM; Srinivasa Rao PVLN; Siva Kumar V
Ren Fail; 2018 Nov; 40(1):534-540. PubMed ID: 30277113
[TBL] [Abstract][Full Text] [Related]
19. Associations of plasma pentraxin 3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease.
Nishi K; Imamura T; Kitamura K; Ogawa T; Fujimoto S; Kakitsubata Y; Ishikawa T; Asada Y; Kodama T
Ren Fail; 2011; 33(4):398-404. PubMed ID: 21529268
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory cytokines and malnutrition as related to risk for cardiovascular disease in hemodialysis patients.
Perunicic-Pekovic G; Pljesa S; Rasic-Milutinovic Z; Stankovic S; Ilic M; Maletic R
Can J Physiol Pharmacol; 2008 Apr; 86(4):205-9. PubMed ID: 18418430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
